ArticleJACC. Case reports2025
Leadless Pacemaker Implantation After Tricuspid Valve Replacement.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intracardiac echocardiography-guided implantation of an active-fixation ventricular leadless pacemaker through a transcatheter tricuspid valve replacement.HeartRhythm case reports · 2026Article
- Leadless pacemaker implantation via right jugular approach in a patient with a bicaval valve system: a case report.European heart journal. Case reports · 2026Article
- Leadless pacemaker placement in a patient with a bicaval stent transcatheter tricuspid valve replacement.HeartRhythm case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid valve disease is gaining clinical significance, with transcatheter tricuspid valve replacement (TTVR) emerging as a viable alternative to surgery. Atrioventricular block is a known postprocedural complication. To avoid interference with the valve prosthesis, leadless pacemakers (LPMs) are preferred over transvenous systems. CASE SUMMARY: An 87-year-old woman developed symptomatic bradycardic atrial fibrillation 3 months after TTVR with an Evoque prosthesis (Edwards Lifesciences). Given her age and comorbidities, an AVEIR VR (Abbott Medical) LPM was implanted via right jugular vein approach, chosen because of the orientation of the prosthesis. During the first attempt, the pacemaker's helix became entangled in the valve frame despite the use of a protective sleeve. The device was safely retrieved, and a second attempt was successful. Postimplantation imaging confirmed preserved valve function. DISCUSSION: This case underscores the importance of individualized procedural planning for LPM implantation after TTVR. The jugular approach, combined with tailored fluoroscopic angulation, can improve catheter control and reduce the risk of prosthesis interaction. TAKE-HOME MESSAGE: LPM implantation after TTVR is feasible. Optimal access selection, imaging strategy, and sheath handling are essential to minimize complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.